Lupin Launches Dapagliflozin Tablets in U.S. Market
Mumbai, India & Naples, Florida | April 10, 2026 Lupin Limited has announced the U.S. launch of Dapagliflozin Tablets...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Mumbai, India & Naples, Florida | April 10, 2026 Lupin Limited has announced the U.S. launch of Dapagliflozin Tablets...
WASHINGTON, April 8, 2026 Vanda Pharmaceuticals Inc. has announced the initiation of the Thetis clinical trial evaluating NEREUSâ„¢ (tradipitant)...
MUMBAI, India and NAPLES, Fla., April 7, 2026 Lupin Limited has received approval from the U.S. Food and Drug...
SEOUL, SOUTH KOREA | January 27, 2026 — Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced a...
BRIDGEWATER, N.J., and BENGALURU, India – October 16, 2025: Biocon Biologics Ltd., a global leader in biosimilars, has expanded...
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
